Genkyotex’s GKT831 Prevents Multiple Complications of Portal Hypertension in Preclinical Model

NEXT STORY
Basilea erweitert Phase-2-Studie mit Derazantinib beim intrahepatischen Gallengangskarzinom (iCCA) um Studienkohorte für Patienten mit Mutation oder Amplifikation des FGFR2-Gens
PREV STORY
ESPERITE N.V. (ESP) publishes its half-year report. Revenues, results and consolidated equity were impacted by adverse market conditions on the stem cell business.
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Harpoon Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

author_avatar
NASDAQ Market News

Invuity Announces 2015 Fourth Quarter, Full Year Results and Conference Call Date

SAN FRANCISCO, Feb. 10, 2016 (GLOBE NEWSWIRE) -- Invuity, Inc. (NASDAQ:IVTY), an advanced medical ...

author_avatar
NASDAQ Market News

Roche’s TECENTRIQ in combination with chemotherapy helped people with previously-untreated extensive-stage small cell lung cancer live significantly longer compared to chemotherapy

IMpower133 is the first Phase III study with an immunotherapy-based combination to show improvement ...

author_avatar
NASDAQ Market News